PillRx only · Injection, Solution · Intramuscular
Tobramycin
Tobramycin Sulfate
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.650
Latest avg · Jul 22, 2026
-20%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
520
Rx · 2026 Q1
33K
Units dispensed
-23%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Hospira, Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jul 17, 2026RESOLVEDShortage resolved: Tobramycin Sulfate Injection (Hospira, Inc., a Pfizer Company)
Tobramycin Sulfate Injection — reported in shortage by Hospira, Inc., a Pfizer Company. Therapeutic category: Anti-Infective.
- Jul 17, 2026SHORTAGEDrug shortage: Tobramycin Sulfate Injection (Hospira, Inc., a Pfizer Company)
Tobramycin Sulfate Injection — reported in shortage by Hospira, Inc., a Pfizer Company. Therapeutic category: Anti-Infective.